Sympathomimetic effects of MIBG: Comparison with tyramine

Journal of Nuclear Medicine

Volumn 40, Issue 8, 1999, Pages 1342-1351

  Graefe, Karl Heinz ^a   Bossle, Franz ^b   Wölfel, Reinhard ^b   Burger, Albrecht ^b   Souladaki, Maria ^b   Bier, Dirk ^b   Dutschka, Klaus ^b   Farahati, Jamshid ^b   Bönisch, Heinz ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b NONE

Author keywords

Indirect sympathomimetic action; Metaiodobenzylguanidine; Neuronal uptake; Tyramine; Vesicular monoamine transporter

Indexed keywords

(3 IODOBENZYL)GUANIDINE; CATECHOLAMINE; DOPAMINE RECEPTOR; NORADRENALIN; TYRAMINE;

ANIMAL TISSUE; ARTICLE; CATECHOLAMINE UPTAKE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG EFFECT; DRUG UPTAKE; FEMALE; HEART RATE; HUMAN; HUMAN CELL; INTRINSIC SYMPATHOMIMETIC ACTIVITY; MALE; MEMBRANE VESICLE; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RABBIT;

3-IODOBENZYLGUANIDINE; ADRENERGIC ALPHA-AGONISTS; ADRENERGIC UPTAKE INHIBITORS; ANIMALS; CATTLE; CHROMAFFIN GRANULES; FEMALE; HEART; HEART RATE; HUMANS; MALE; MYOCARDIUM; NOREPINEPHRINE; RABBITS; RADIOPHARMACEUTICALS; RESERPINE; SYMPATHOMIMETICS; TUMOR CELLS, CULTURED; TYRAMINE;

EID: 0032818908     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. 123I-MIBG. Med Pediatr Oncol. 1987;15:170-177.
2. Wafelman AR, Hoefnagel CA, Maes RAA, Beijnen JH. Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med. 1994;21:545-559.
3. Farahati J, Mueller SP, Coenen HH, Reiners C. Scintigraphy of neuroblastoma with radioiodinated m-iodobenzylguanidine. In: Treves ST, ed. Paediatric Nuclear Medicine, 2nd ed. New York, NY: Springer; 1995:528-545.
4. Iversen LL. The Uptake and Storage of Noradrenaline in Sympathetic Nerves. Cambridge, UK: Cambridge University Press; 1967.
5. Wieland DM, Brown LE, Rogers WL, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med. 1981;22:22-31.
6. Nakajo M, Shimabukuro K, Yoshimura H, et al. Iodine-131 meta-iodobenzylguanidine intra-and extravesicular accumulation in the rat heart. J Nucl Med. 1986;27:84-89.
7. Jaques S, Tobes MC, Sisson JC, Baker JA, Wieland DM. Comparison of the sodium dependency of uptake of meta-iodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells. Mol Pharmacol. 1984;26:539-546.
8. Tobes MC, Jaques S, Wieland DM, Sisson JC. Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med. 1985;26: 897-907.
9. 125I] iodobenzylguanidine in the human neuroblastoma cell line SK-N-SH1. Cancer Res. 1985;45:6366-6370.
10. Smets LA, Janssen M, Rutgers M, Ritzen K, Buitenhuis C. Pharmacokinetics and intracellular distribution of the tumor-targeted radiopharmaceutical m-iodobenzylguanidine in SK-N-SH neuroblastoma and PC-12 pheochromocytoma cells. Int J Cancer. 1991;48:609-615.
11. Gasnier B, Roisin M-P, Scherman D, Coornaert S, Desplanches G, Henry J-P. Uptake of meta-iodobenzylguanidine by bovine chromaffin granule membranes. Mol Pharmacol. 1986;29:275-280.
12. 123I]iodobenzylguanidine in isolated rat heart. Nucl Med Biol. 1995;22:1-12.
13. 131I-meta-iodobenzylguanidine uptake in the isolated rat lung: a potential marker of endothelial cell function. Eur J Nucl Med. 1988;13:543-547.
14. Rutgers M, Tytgat GAM, Verwijs-Janssen M, Buitenhuis C, Voute PA, Smets LA. Uptake of the neuron-blocking agent meta-iodobenzylguanidine and serotonin by human platelets and neuro-adrenergic tumour cells. Int J Cancer. 1993;54:290-295.
15. 131I]-meta-iodobenzylguanidine: concise communication. J Nucl Med. 1981;22:358-364.
16. 131I-meta-iodobenzylguanidine in patients with melastatic pheochromocytoma. J Nucl Med. 1986;27:37-44.
17. 131I]-iodobenzylguanidine. J Nucl Med. 1980;21:349-353.
18. 123I]-iodophenyl)tropane-2β-carboxylic acid methylester by nonisotopic, Cu(I)-assisted halogen exchange [in German]. Nucl Med. 1994;33:A11.
19. Lowry OH, Rosebrough NJ, Farr AL, Randall RF. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
20. Kobold G, Langer R, Burger A. Does the carrier of chromaffin granules transport the protonated or the uncharged species of catecholamines? Naunyn Schmiedebergs Arch Pharmacol. 1985;331:209-219.
21. Michalke W, Langer R, Burger A. Ghosts of chromaffin granules accumulate biogenic amines according to a "pump and leak system" without contribution of carrier-mediated efflux. Naunyn Schmiedebergs Arch Pharmacol. 1990;342:312-322.
22. 50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099-3108.
23. Fischer P, Burger A, Graefe K-H, Trendelenburg U. The effect of (±)-dobutamine on adrenergic nerve endings. Naunyn Schmiedebergs Arch Pharmacol. 1989;339: 79-84.
24. 3H-noradrenaline. Naunyn Schmiedebergs Arch Pharmacol. 1987;336:611-620.
25. Bönisch H, Trendelenburg U. The mechanism of action of indirectly acting sympathomometic amines. In: Trendelenburg U, Weiner N, eds. Catecholamines II. Handbook of Experimental Pharmacology, vol. 90/I. Berlin, Germany: Springer; 1988:247-277.
26. Richards ML, Sadee W. Human neuroblastoma cell lines as models of catechol uptake. Brain Res. 1986;384:132-137.
27. Bryan-Lluka LJ, Bönisch H. Lanthanides inhibit the human noradrenaline, 5-hydroxytryptamine and dopamine transporters. Naunyn Schmiedebergs Arch Pharmacol. 1997;355:699-706.
28. Erickson JD, Schäfer M K-H, Bonner TI, Eiden LE, Weihe E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA. 1996;93:5166-5171.
29. Henry JP, Sagné C, Botton D, Isambert MF, Grasnier B. Molecular pharmacology of the vesicular monoamiune transporter. In: Goldstein DS, Eisenhofer G, McCarty R, eds. Catecholamines: Bridging Basic Science with Clinical Medicine. London, UK: Academic Press; 1998:236-239.
30. Smets LA, Loesberg C, Janssen M, Metwally EA, Huiskamp R. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells. Cancer Res. 1989;49:2941-2944.
31. Wafelman AR, Konings MCP, Rosing H, et al. High-performance liquid chromatographic determination of metaiodobenzylguanidine in whole blood and plasma of cancer patients. J Pharm Biomed Anal. 1994;12:1173-1179.
32. Farahati J, Coenen HH, Dutschka K, et al. Effect of specific activity on neuroblastoma uptake of I-123-meta-iodobenzylguanidine in nude mice xeno-grafted with SK-N-SH cells. Oncol Reports. 1997;4:363-366.
33. Loesberg C, Van-Rooij H, Nooijen WJ, Meijer AJ, Smets LA. Impaired mitochondrial respiration and stimulated glycolysis by m-iodobenzylguanidine (MIBG). Int J Cancer. 1990;46:276-281.
34. Van den Berg J, Smets LA, Rutgers M, et al. Chemical characterization and comparative cellular effects of meta-iodobenzyl guanidine and benzyl guanidine. Cancer Chemother Pharmacol. 1997;40:131-137.